Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $26

Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on LENZ Therapeutics (NASDAQ: LENZ) but has lowered the price target from $52 to $26.